Highlights include how cost-effective insulin reduces hospital visits; prevalence of restrictive lung disease in T2DM patients; and the wonders of self-monitoring for cost of care.
Endocrinology Month in Review: April 2024
Diabetes Dialogue: 2024 ACP Type 2 Diabetes Recommendations
ACP's New Type 2 Diabetes Guidance Recommends SGLT2is, GLP-1 RAs as Second-Line to Metformin
Diabetes Dialogue: STEP HFpEF DM and Fair Allocation of Incretin-Based Therapies
Insulin Glargine Biosimilar Demonstrates Bioequivalence to Originator for Type 2 Diabetes
Poorly Controlled Type 1 Diabetes Associated with MASLD in Children, Adolescents